Skip to main content
Year archive

Formycon AG — 2020 filings

All 21 regulatory filings released by Formycon AG (FYB) in 2020, sourced directly from the official regulator.

21 Filings
2020 Period
2020 filings (21)
Filing Released Lang
Formycon Reports on Virtual Annual General Meeting 2020
AGM Information
2020-12-14 English
Innovative SARS-CoV-2 Blocker from Formycon Completely Prevents Infection of Cells
Regulatory Filings
2020-12-09 English
Chief Operating Officer Dr. Stefan Glombitza appointed to Formycon AG's Management Board for another Four Years
Board/Management Information
2020-11-24 English
Formycon Reports its Nine-month Figures for 2020
Earnings Release 9M 2020
2020-11-11 English
Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R)* (Ustekinumab)
Regulatory Filings
2020-11-09 English
Formycon informs about the modified BLA-Submission Strategy for its Lucentis(R)* Biosimilar-Candidate FYB201
Legal Proceedings Report
2020-11-05 English
Formycon Announces Virtual Annual General Meeting for December 10, 2020
AGM Information
2020-11-02 English
Formycon Receives Funding for COVID-19 Drug Research from the Bavarian Research Foundation
Regulatory Filings
2020-10-13 English
Strategic Investor Active Ownership Group Subscribes for Cash Capital Increase of EUR 25.75 million
Share Issue/Capital Change
2020-10-12 English
Formycon places Cash Capital Increase of 25.75 Million Euros with Strategic Investor
Capital/Financing Update
2020-10-12 English
Half-yearly financial statements 2020
Interim / Quarterly Report H2 2020
2020-09-29 English
Formycon Announces Half-Year Results for 2020
Earnings Release H1 2020
2020-09-23 English
Formycon and Bioeq Enroll First Patient in Phase III Study with Aflibercept Biosimilar (FYB203)
Regulatory Filings
2020-08-24 English
Formycon Reports Financial Results for the First Quarter of 2020
Earnings Release Q1 2020
2020-06-22 English
Annual financial statements 2019
Annual Report FY 2019
2020-05-25 German
Formycon Publishes Annual Financial Statements for the 2019 Financial Year
Report Publication Announcement
2020-05-18 English
Formycon Announces Update on Biosimilar Programs
Regulatory Filings
2020-05-15 English
Formycon is postponing the general assembly into the fourth quarter of 2020 to maintain the possibility of an event in person
AGM Information
2020-05-11 English
Formycon Starts Antibody-Based Drug Development for COVID-19
Regulatory Filings
2020-04-29 English
Datum:21.02.2020
Annual Report FY 2018
2020-02-21 German
Formycon informs about the current Status of the BLA Review Process of the Lucentis(R)* Biosimilar Candidate FYB201
Legal Proceedings Report
2020-02-04 English